Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitors

Languages

Service navigation

Search

Contact information

Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitors

The aim of the HTA is to evaluate the efficacy, safety, cost-effectiveness and budget impact of long-term continuous proton pump inhibitor (PPI) therapy compared to long-term on-demand PPI therapy in patients with non-erosive reflux disease (NERD) and patients with uninvestigated gastroesophageal reflux disease (GERD).

Dokumente

HTA report (PDF, 3 MB, 17.06.2020)

Stakeholder feedback on the HTA report (PDF, 251 kB, 17.06.2020)

Scoping report (PDF, 1 MB, 01.10.2019)

Stakeholder feedback on the scoping report (PDF, 349 kB, 01.10.2019)

< back to HTA projects

Last modification 17.06.2020

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/protonenpumpeninhibitoren.html